// App-Quantinova.ai

3028 : ERK signal suppression and sensitivity to CH5183284/Debio 1347, a selective FGFR inhibitor

Researchers

Presenter

  • Yoshito Nakanishi

Principal Investigators

  • Hideaki Mizuno

  • Hitoshi Sase

  • Toshihiko Fujii

  • Kiyoaki Sakata

  • Nukinori Akiyama

  • Yuko Aoki

  • Masahiro Aoki

  • Nobuya Ishii

Medical Centers

  • Chugai Pharmaceutical Co., Ltd., KAMAKURA, Japan.

Locations

  • Japan

Companies

  • Chugai Pharmaceutica

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Mitogen-activated protein kinase

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Fibroblast growth factor receptor 1

  • Fibroblast Growth Factor Receptor 2

  • PI3K/AKT

Drug/Treatment

  • Debio 1347

Outcome

  • N/A

Study Design

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved